title: Editorial commentary: Prophylactic echinocandin: is there a subgroup of intensive care unit patients who benefit?
authors.affiliation: The National Aspergillosis Centre, University Hospital of South Manchester, The University of Manchester, Manchester Academic Health Science Centre, United Kingdom.
authors.forename: Eavan G
authors.initials: EG
authors.lastname: Muldoon
authors.forename: David W
authors.initials: DW
authors.lastname: Denning
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D058365:Candidiasis, Invasive / Q000517:prevention & control*; D000077336:Caspofungin; D054714:Echinocandins / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007362:Intensive Care Units; D055666:Lipopeptides; D008297:Male
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077336:Caspofungin
keywords: anidulafungin; candidaemia; caspofungin; micafungin; peritonitis